Evidence map›Paper›PMID 35108303›Full record

ArticlePloS one2022

Computational prediction of intracellular targets of wild-type or mutant vesicular stomatitis matrix protein.

Matthew C Morris, Thomas M Russell, Cole A Lyman, Wesley K Wong, Gordon Broderick, Maureen C Ferran

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Matthew C MorrisCenter for Clinical Systems Biology, Rochester General Hospital, Rochester, NY, United States of America.
Thomas M RussellThomas Gosnell School of Life Sciences, Rochester Institute of Technology, Rochester, NY, United States of America.
Cole A LymanCenter for Clinical Systems Biology, Rochester General Hospital, Rochester, NY, United States of America.ORCID 0000-0001-7921-165X
Wesley K WongThomas Gosnell School of Life Sciences, Rochester Institute of Technology, Rochester, NY, United States of America.
Gordon BroderickCenter for Clinical Systems Biology, Rochester General Hospital, Rochester, NY, United States of America.ORCID 0000-0002-3588-8252
Maureen C FerranThomas Gosnell School of Life Sciences, Rochester Institute of Technology, Rochester, NY, United States of America.ORCID 0000-0002-0515-8582
Rochester General Hospital · USRochester Institute of Technology · US

Funding

NFkB-dependent antiviral pathways in VSV-resistant cancer cellsR15CA246419 · NCI · ROCHESTER INSTITUTE OF TECHNOLOGY · PI FERRAN, MAUREEN C · 2021 to 2021
$451k
NCI NIH HHS R15 CA246419
6 · The paper itself

Abstract

The matrix (M) protein of vesicular stomatitis virus (VSV) has a complex role in infection and immune evasion, particularly with respect to suppression of Type I interferon (IFN). Viral strains bearing the wild-type (wt) M protein are able to suppress Type I IFN responses. We recently reported that the 22-25 strain of VSV encodes a wt M protein, however its sister plaque isolate, strain 22-20, carries a M[MD52G] mutation that perturbs the ability of the M protein to block NFκB, but not M-mediated inhibition of host transcription. Therefore, although NFκB is activated in 22-20 infected murine L929 cells infected, no IFN mRNA or protein is produced. To investigate the impact of the M[D52G] mutation on immune evasion by VSV, we used transcriptomic data from L929 cells infected with wt, 22-25, or 22-20 to define parameters in a family of executable logical models with the aim of discovering direct targets of viruses encoding a wt or mutant M protein. After several generations of pruning or fixing hypothetical regulatory interactions, we identified specific predicted targets of each strain. We predict that wt and 22-25 VSV both have direct inhibitory actions on key elements of the NFκB signaling pathway, while 22-20 fails to inhibit this pathway.

Indexed as

TranscriptomeAnimalsComputational BiologyFibroblastsInterferon Type IMiceMutant ProteinsNF-kappa BVesicular StomatitisVesicular stomatitis Indiana virusViral Matrix ProteinsInterferon Type IM protein, Vesicular stomatitis virusMutant ProteinsNF-kappa BViral Matrix Proteins

Identifiers

PMID35108303
PMCPMC8809538
OpenAlexW4210487445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.